ArticlesNeurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study
Introduction
Lewy body disorders such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB) have a prodromal period of several years, during which neuropathological changes are thought to occur before parkinsonism and dementia become manifest. This prodromal phase provides an opportunity to study early disease events and disease progression, and allows the testing of novel interventions that could slow or prevent the neurodegenerative process. Identification of individuals in the prodromal period of these disorders remains a major challenge. One possible approach is to detect markers of this period that could identify the future conversion to PD and DLB with high specificity and positive predictive value.1, 2, 3
Evidence exists that olfactory loss, constipation, and depression can antedate the diagnosis of PD by several years.1, 4, 5, 6, 7, 8, 9 However, these features are common in the general population, and they are most often the result of causes other than incipient PD.10, 11, 12 Therefore, the specificity and positive predictive value of olfactory loss, constipation, and depression for the identification of underlying PD seems low. Rapid-eye-movement (REM) sleep behaviour disorder (RBD; a parasomnia characterised by dream-enacting behaviours and loss of REM sleep atonia) has also been described as an initial manifestation of PD and DLB.13, 14, 15 Results from longitudinal studies from three different groups have shown that patients with the idiopathic form of RBD (IRBD) eventually develop a Lewy body disorder. In one study,16 parkinsonism developed in 11 (38%) of 29 patients with IRBD nearly 4 years after the diagnosis of IRBD. After 16 additional years of follow-up, 21 patients with IRBD from the original cohort developed PD, DLB, or multiple system atrophy.17 In a second series, 26 (28%) of 93 patients with IRBD developed PD, DLB, or multiple system atrophy after a mean follow-up of 5 years.18 In a study done in our institution,19 20 (45%) of 44 patients with IRBD developed a defined neurodegenerative syndrome after a mean follow-up of 5 years.19 Emerging disorders were PD, DLB, and less frequently multiple system atrophy and mild cognitive impairment. We showed that patients who developed a motor or cognitive disorder were those with a longer clinical follow-up,19 which suggested that the conversion rate might increase with extended follow-up. A very high rate of conversion would indicate that IRBD represents the prodromal phase of a Lewy body disorder or, much more rarely, multiple system atrophy, both deemed α-synucleinopathies. To test this hypothesis, we aimed to identify the frequency and nature of the defined neurodegenerative syndromes that emerged in our original cohort after 7 years of additional follow-up.
Section snippets
Participants
In a previous study done in 2005,19 we assessed the first 44 consecutive self-referred patients with IRBD (39 men and five women with a mean age of 74 years) who were diagnosed at our sleep unit between 1991 and 2003 in the Hospital Clínic de Barcelona, Barcelona, Spain. Diagnosis of IRBD required a history of dream-enacting behaviours, video-polysomnographic confirmation of increased electromyographic activity during REM sleep associated with abnormal behaviours, no cognitive complaints, and
Results
We previously reported that by the 2005 assessment, 20 (45%) of 44 patients developed a defined neurodegenerative syndrome after a median interval of 11 years (range 5–23) from the estimated onset of RBD symptoms, and after a median follow-up of 4·5 years (range 2–15).19 Nine patients were diagnosed with PD, six with DLB, one with multiple system atrophy, and four with mild cognitive impairment (figure 1). During the additional 7-year follow-up period, seven of the individuals who were
Discussion
These findings show that most individuals with IRBD develop a Lewy body disorder with time. All four patients who were deemed neurological-disease-free at the end of this study showed at least one marker of increased short-term risk for developing a Lewy body disorder, such as decreased striatal DAT uptake, substantia nigra hyperechogenicity, and hyposmia.26, 27, 28 According to our findings and those of others (panel),17, 18, 45 we are tempted to speculate that most, if not all, patients with
References (71)
Prevalence and clinical course of depression: a review
Clin Psychol Rev
(2011)- et al.
The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases
Sleep Med Rev
(2009) - et al.
Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study
Lancet Neurol
(2006) - et al.
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study
Lancet Neurol
(2010) - et al.
Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study
Lancet Neurol
(2011) - et al.
A lesson from anatomy: focal brain lesions causing REM sleep behavior disorder
Sleep Med
(2009) - et al.
Staging of brain pathology related to sporadic Parkinson's disease
Neurobiol Aging
(2003) - et al.
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
Lancet Neurol
(2009) - et al.
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Alzheimers Dement
(2012) - et al.
Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder
Brain Res Bull
(2006)
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study
Lancet Neurol
Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease
Neurobiol Aging
Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease
Sleep Med
Dementia with Lewy bodies
Lancet Neurol
Multiple system atrophy
Lancet Neurol
Diagnosis and the premotor phase of Parkinson's disease
Neurology
Defining at-risk populations for Parkinson's disease: lessons from ongoing studies
Mov Disord
Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease
Mov Disord
Association of olfactory dysfunction with risk for future Parkinson's disease
Ann Neurol
Frequency of bowel movements and the future risk of Parkinson's disease
Neurology
Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study
Acta Psychiatr Scand
Major depressive disorder in Parkinson's disease: a register-based study
Acta Psychiatr Scand
Higher incidence of depression preceding the onset of Parkinson's disease: a register study
Mov Disord
Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism
Neurology
Prevalence of olfactory impairment in older adults
JAMA
Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis
Am J Gastroenterol
REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions
Ann NY Acad Sci
REM sleep behavior disorder: motor manifestations and pathophysiology
Mov Disord
Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder
Neurology
Delayed emergence of a parkinsonian disorder or dementia in 81% of older males initially diagnosed with idiopathic REM sleep behavior disorder (IBD): 16 year update on a previously reported series
Sleep Med
Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder
Neurology
Unified Parkinson's Disease Rate Scale
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases
J Neurol Neurosurg Psychiatry
DSM-IV-TR. Diagnostic and statistical manual of mental disorders
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium
Neurology
Cited by (551)
α-synuclein antibody 5G4 identifies idiopathic REM-sleep behavior disorder in abdominal skin biopsies
2024, Parkinsonism and Related DisordersSarcopenia in patients with isolated rapid eye movement sleep behavior disorder
2024, Sleep MedicineThe raphe nuclei are the early lesion site of gastric α-synuclein propagation to the substantia nigra
2024, Acta Pharmaceutica Sinica BPeripheral α-synuclein isoforms are potential biomarkers for diagnosis and prognosis of isolated REM sleep behavior disorder
2023, Parkinsonism and Related Disorders